1,232 results on '"Kim, Byoung-Gie"'
Search Results
2. Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
3. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
4. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial
5. ASO Visual Abstract: Comparison of Minimally Invasive and Open Surgery for the Treatment of Endometrial Cancer with a High Risk of Recurrence: A Propensity-Score-Matching Study in Korea and Taiwan
6. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
7. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.
8. Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.
9. An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).
10. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women
11. Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)
12. Polygenic risk modeling for prediction of epithelial ovarian cancer risk
13. Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience
14. Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
15. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
16. Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study
17. Advantages of laparoscopy in gynecologic surgery in elderly patients
18. Comparison of RNA-Seq and microarray in the prediction of protein expression and survival prediction
19. Risk Factors Affecting Clinical Outcomes of Low-risk Early-stage Human Papillomavirus–Associated Endocervical Adenocarcinoma Treated by Surgery Alone: Application of Silva Pattern
20. The efficacy of subsequent chemotherapy in ovarian cancer patients who progressed in prior PARPi
21. Identification of tumor-specific genes in cervix sample of ovarian cancer patients
22. DOMENICA study (GINECO-EN105b/ENGOT-en13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1)
23. Preliminary efficacy of pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/APGOT-OV3)
24. A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
25. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
26. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): a phase II umbrella trial
27. GX-188E DNA Vaccine Plus Pembrolizumab as a 2nd Line Treatment for HPV 16- and/or 18-Positive, PD-L1 All-Comer Recurrent or Advanced Cervical Cancer: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
28. Initial experience with the enhanced recovery after surgery (ERAS) protocols in gynecologic surgery at an urban academic tertiary medical center
29. Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
30. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
31. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
32. Metabolic syndrome and persistent cervical human papillomavirus infection
33. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
34. AIM2CERV: a randomized phase III study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk locally advanced cervical cancer (HRLACC)
35. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
36. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer
37. Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study.
38. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer
39. In Vivo Comparison of MONOFIX, A Novel Barbed Suture with a Triangular Stopper, with Pre-existing Products in a Porcine Model
40. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer
41. TP003/#1557 An open label, single arm, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16 or 18 positive cervical cancer (DURBAC)
42. PO010/#673 A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)
43. TP016/#1542 A multicenter study of niraparib as maintenance therapy in BRCA wild-type, newly diagnosed advanced ovarian cancer (Polo trial)
44. EP011/#717 Prediction of chemotherapy response with liquid biopsy of body fluid from patients with gynecologic cancer
45. 504 Anti-cancer activities of EU103 in a preclinical model of ovarian cancer
46. EP128/#505 Impact of different adjuvant treatment approaches on survival in high-risk endometrial carcinoma: a multicenter study
47. EP012/#719 Genome-wide cell-free DNA analysis algorithms for early detection and prediction of prognosis of ovarian cancer
48. EP256/#833 Retrospective analysis comparing the survival outcome of niraparib and olaparib in advanced ovarian cancer patients
49. EP138/#520 Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low risk endometrial cancer patients: a Korean gynecologic oncology group ancillary study
50. PR008/#805 Efficacy and safety of BVAC-C in HPV type 16 or 18 positive cervical carcinoma who failed 1st platinum based chemotherapy: a phase I/IIA study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.